目的 探討培哚普利聯(lián)合吲達(dá)帕胺對(duì)鹽敏感性和非鹽敏感性高血壓的臨床療效和安全性。方法 將上海市虹口區(qū)江灣鎮(zhèn)街道社區(qū)衛(wèi)生服務(wù)中心2013年2月-2014年2月收治的128例高血壓患者根據(jù)鹽敏感性檢測(cè)分為敏感組（66例）和非敏感組（62例），研究開(kāi)始后兩組患者均口服培哚普利片4 mg/d；吲達(dá)帕胺緩釋膠囊1.5 mg/d，并根據(jù)血壓逐漸調(diào)整用量，治療8周后比較兩組臨床療效、收縮壓（SBP）、舒張壓（DBP）、左心室重量指數(shù)（LVMI）、血漿血管緊張素Ⅱ（AngⅡ）和醛固酮（ALD）水平。結(jié)果 敏感組和非敏感組的總有效率分別為80.30%、70.97%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組患者SBP、DBP和LVMI均較治療前有所減少，且敏感組減少程度更為顯著，與非敏感組相比差異具有統(tǒng)計(jì)學(xué)意義（P<0.01）。兩組患者AngⅡ和ALD水平均較治療前下降，與治療前相比差異均有統(tǒng)計(jì)學(xué)意義（P<0.01），且治療后敏感組AngⅡ水平低于非敏感組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 培哚普利聯(lián)合吲達(dá)帕胺能夠調(diào)節(jié)患者血漿AngⅡ和ALD水平，對(duì)鹽敏感和非鹽敏感性高血壓均有較好的降壓作用，且對(duì)鹽敏感性高血壓降壓作用更為顯著。

Objective To explore the clinical efficacy and safety of perindopril combined with indapamide in the treatment of salt sensitivity/non salt sensitive hypertension. Methods Hypertension patients (128 cases) in Jiangwan Community Health Center of Hongkou District of Shanghai City from 2013 February to 2014 February were divided into sensitive (66 cases) and non sensitive (62 cases) groups according to the salt sensitivity test. After the beginning of the study, all the patients were given Perindopril Tablet 4 mg/d; Indapamide Sustained Release Capsules 1.5 mg/d, then the dosages were gradually adjusted according to the blood pressure, compared the systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular mass index (LVMI), plasma angiotensin II (Ang II), and aldosterone (ALD) levels between the two groups after 8 weeks of the treatment. Results The total effective rates were 80.30% and 70.97% in the sensitive and non sensitive group, and there was significant difference between the two groups (P < 0.05). SBP, DBP, and LVMI levels decreased more after the treatment in the two groups than before the treatment, and the levels in the sensitive group decreased more obvious degree, the difference was statistically significant compared with non sensitive group (P < 0.01). Ang Ⅱ and ALD levels decreased after the treatment in the two groups than before the treatment (P < 0.01), and after the treatment the Ang II level in the sensitive group was lower than that in the non sensitive group, and there was significant difference between the two groups (P < 0.05). Conclusion Perindopril combined with indapamide could regulate the Ang II levels in plasma of patients with hypertension, which has obvious antihypertensive effect to the both sensitive and non salt hypertension, but the effect on salt sensitive hypertension patients is obvious.